AVIR
NASDAQ
US
Atea Pharmaceuticals, Inc. - common stock
$5.76
▲ +$0.11
(+1.95%)
Vol 443K
3
Quality Score
fail
Rev ✗
NI ✗
>IPO ✗
Mkt Cap
$278.9M
ROE
-38.4%
Margin
34.5%
D/E
0.00
Beta
0.26
52W
$2–$4
Wall Street Consensus
9 analysts · Apr 20263
Strong Buy
4
Buy
2
Hold
0
Sell
0
Strong Sell
77.8%
Buy Rating
Price Chart
Similar Stocks
ZVRA
Zevra Therapeutics Inc
P/E 14.3
$504.4M
CRMD
CorMedix Inc
P/E 5.6
$916.3M
FULC
Fulcrum Therapeutics Inc
$746.1M
ACRS
Aclaris Therapeutics Inc
$326.1M
AQST
Aquestive Therapeutics Inc
$788.1M
CTNM
Contineum Therapeutics Inc
$417.5M
SIGA
SIGA Technologies Inc
P/E 5.9
$437.5M
PLYX
Polaryx Therapeutics, Inc
Earnings
Beat rate: 25.0%
Next Report
May 11, 2026
EPS Estimate: $-0.60
| Quarter | EPS Est | EPS Act | Surprise |
|---|---|---|---|
| Mar 2026 | $-0.60 | — | — |
| Dec 2025 | $-0.54 | $-0.57 | $-0.03 |
| Sep 2025 | $-0.45 | $-0.53 | $-0.08 |
| Jun 2025 | $-0.42 | $-0.44 | $-0.02 |
Quarterly Revenue & Earnings
| Quarter | 2024-1… | 2025-0… | 2025-0… | 2025-0… | 2025-1… |
|---|---|---|---|---|---|
| Revenue | — | — | — | — | — |
| Net Income | -$33.5M | -$34.3M | -$37.2M | -$42.0M | -$44.9M |
Fundamentals Trend
| Metric | 2025-06-30 | 2025-09-02 | 2025-10-02 | 2025-11-03 | 2025-12-03 | 2026-01-02 |
|---|---|---|---|---|---|---|
| ROE (TTM) | -32.6% | -32.6% | -32.6% | -32.6% | -32.6% | -38.4% |
| P/E (TTM) | — | — | — | — | — | — |
| Net Margin | — | 34.5% | 34.5% | 34.5% | 34.5% | 34.5% |
| Gross Margin | — | — | — | — | — | — |
| D/E Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Current Ratio | 19.17 | 19.17 | 19.17 | 19.17 | 19.17 | 16.66 |
Key Ratios
ROA (TTM)
-35.9%
P/S (TTM)
0.79
P/B
0.6
EPS (TTM)
$-1.78
CF/Share
$-1.57
52W High
$4.02
52W Low
$2.46
$2.46
52-Week Range
$4.02
Financial Health
Free Cash Flow
-$28.2M
Net Debt
-$94.9M
Cash
$95.7M
Total Debt
$843K
As of Dec 31, 2025
How does AVIR compare to Pharmaceuticals peers?
Peer group: Micro-cap Pharmaceuticals (All) · 171 companies
AVIR valuation vs Pharmaceuticals peers
P/E ratio
—
▼
0%
below
peers
(22.4)
vs Peers
vs Industry
Undervalued
P/S ratio
0.8
▼
84%
below
peers
(5.0)
vs Peers
vs Industry
Undervalued
P/B ratio
0.6
▼
70%
below
peers
(2.1)
vs Peers
vs Industry
Undervalued
Div yield
—
▼
0%
below
peers
(2.0%)
vs Peers
vs Industry
Low yield
AVIR profitability vs Pharmaceuticals peers
ROE
-38.4%
▲
29%
above
peers
(-54.3%)
vs Peers
vs Industry
Below avg
Net margin
34.5%
▲
173%
above
peers
(-47.4%)
vs Peers
vs Industry
Below avg
Gross margin
—
▼
0%
below
peers
(68.3%)
vs Peers
vs Industry
In line
ROA
-35.9%
▲
4%
above
peers
(-37.4%)
vs Peers
vs Industry
In line
AVIR financial health vs Pharmaceuticals peers
D/E ratio
0.0
▼
100%
below
peers
(1.5)
vs Peers
vs Industry
Low debt
Current ratio
16.7
▲
396%
above
peers
(3.4)
vs Peers
vs Industry
Strong liquidity
Beta
0.3
▼
72%
below
peers
(0.9)
vs Peers
vs Industry
More volatile
AVIR fundamentals radar
AVIR
Peer median
Industry
AVIR profitability vs leverage
Bubble size = market cap · X = net margin · Y = D/E ratio